| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jan 23, 2013Milestone in IN.PACT SFA II Brings FDA Submission for Promising Interventional Treatment of Peripheral Artery Disease One Step Closer in U.S.
MINNEAPOLIS -- Jan. 23, 2013 -- Medtronic, Inc. (NYSE: MDT), today announced completion of enrollment in IN.PACT SFA II, the U.S. arm of its clinical study for the IN.PACT Admiral drug-eluting...
-
Jan 10, 2013Medtronic-Sponsored Study Aims to Support Worldwide Indication Expansion for CRT-P in a Significantly Underserved Heart Failure Patient Population
MINNEAPOLIS - Jan. 10, 2013 - Medtronic, Inc. (NYSE: MDT) today announced the first patient enrollment in MIRACLE EF, a global clinical trial that will evaluate the effectiveness of cardiac...
-
Dec 17, 2012Published data demonstrate the Symplicity(TM) renal denervation system provides blood pressure reduction in patients with treatment-resistant hypertension sustained to 12 months
MINNEAPOLIS - December 17, 2012 - Medtronic, Inc. (NYSE: MDT) today announced that one-year results from Symplicity HTN-2, the first randomized clinical trial investigating renal denervation, were...
-
Dec 3, 2012System Designed to Improve Glucose Control in Critical Care Patients
MINNEAPOLIS - December 3, 2012 - Medtronic, Inc. (NYSE:MDT) today announced CE (Conformité Européenne) Mark approval of its innovative Sentrino® Continuous Glucose Management System, the first...
-
Nov 20, 2012Revenue of $4.1 Billion Grew 5% on a Constant Currency Basis; 2% as Reported
MINNEAPOLIS - November 20, 2012 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its second quarter of fiscal year 2013, which ended October 26, 2012. The Company reported...